Comments
Public health concerns and interests of the domestic drug industry will guide India's negotiating position in the India-European Union Broad-based Trade and Investment Agreement (BTIA), the Minister of State for Commerce and Industry, Mr Jyotiraditya M Scindia, said on Monday in a written reply in Lok Sabha.
The BTIA talks are ongoing and final positions have not emerged, he added. He was replying to a question whether the BTIA includes Intellectual Property (IP) related issue that will affect the prospects of the domestic drug industry.
India's stand is based on comprehensive Inter-Ministerial consultations and inputs received from Intellectual Property Rights experts and stakeholders, the Minister said. He added that the Association of Drug Manufacturing Units had voiced their opposition to the proposed inclusion of IP related issues in the BTIA.
India has clarified to the EU negotiations that it cannot accept provisions in the BTIA that are beyond the World Trade Organisation's Trade Related aspects of IP Rights (TRIPS) and domestic law, he added.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.